Discovery, synthesis, and structure-based optimization of a series of N -(tert -Butyl)-2-(N -arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease

Article abstract of DOI:10.1021/jm301580n

A high-throughput screen of the NIH molecular libraries sample collection and subsequent optimization of a lead dipeptide-like series of severe acute respiratory syndrome (SARS) main protease (3CLpro) inhibitors led to the identification of probe compound ML188 (16-(R), (R)-N-(4-(tert-butyl)phenyl)-N- (2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)furan-2-carboxamide, Pubchem CID: 46897844). Unlike the majority of reported coronavirus 3CLpro inhibitors that act via covalent modification of the enzyme, 16-(R) is a noncovalent SARS-CoV 3CLpro inhibitor with moderate MW and good enzyme and antiviral inhibitory activity. A multicomponent Ugi reaction was utilized to rapidly explore structure-activity relationships within S_1′, S ₁, and S₂ enzyme binding pockets. The X-ray structure of SARS-CoV 3CLpro bound with 16-(R) was instrumental in guiding subsequent rounds of chemistry optimization. 16-(R) provides an excellent starting point for the further design and refinement of 3CLpro inhibitors that act by a noncovalent mechanism of action.

Full text of DOI:10.1021/jm301580n

Article
pubs.acs.org/jmc
Discovery, Synthesis, And Structure-Based Optimization of a Series
of N‑(tert-Butyl)-2‑(N‑arylamido)-2-(pyridin-3-yl) Acetamides (ML188)
as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute
Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease
Jon Jacobs,†,‡,§ Valerie Grum-Tokars,⊥ Ya Zhou,†,‡,§ Mark Turlington,†,‡,§ S. Adrian Saldanha,∥
Peter Chase,∥ Aimee Eggler,▽ Eric S. Dawson,†,‡,§ Yahira M. Baez-Santos,▽ Sakshi Tomar,▽
Anna M. Mielech,¶ Susan C. Baker,¶ Craig W. Lindsley,†,‡,§,# Peter Hodder,∥ Andrew Mesecar,*,▽
and Shaun R. Stauffer*,†,‡,§,#
†Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
‡Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United
States
§Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, Tennessee 37232, United States
⊥Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, Illinois 60607, United States
∥Lead Identification Division, Translational Research Institute, Scripps Research Institute Molecular Screening Center, 130 Scripps
Way, Jupiter, Florida 33458, United States
▽Department of Biological Sciences, Purdue University, 915 West State Street, West Lafayette, Indiana 47907, United States
¶Department of Microbiology and Immunology, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois
60153, United States
#Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States
S
* Supporting Information
ABSTRACT: A high-throughput screen of the NIH molecular libraries
sample collection and subsequent optimization of a lead dipeptide-like series of
severe acute respiratory syndrome (SARS) main protease (3CLpro) inhibitors
led to the identification of probe compound ML188 (16-(R), (R)-N-(4-(tert-
butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)furan-2-car-
boxamide, Pubchem CID: 46897844). Unlike the majority of reported
coronavirus 3CLpro inhibitors that act via covalent modification of the
enzyme, 16-(R) is a noncovalent SARS-CoV 3CLpro inhibitor with moderate
MW and good enzyme and antiviral inhibitory activity. A multicomponent Ugi
reaction was utilized to rapidly explore structure−activity relationships within
S1′, S1, and S2 enzyme binding pockets. The X-ray structure of SARS-CoV
3CLpro bound with 16-(R) was instrumental in guiding subsequent rounds of
chemistry optimization. 16-(R) provides an excellent starting point for the further design and refinement of 3CLpro inhibitors
that act by a noncovalent mechanism of action.
person-to-person via respiratory droplets make it particularly
deadly among worldwide pandemic threats. With the
cooperation of leading nations, a rigorous public healthcare
campaign was fortunately successful in controlling the outbreak.
However, a reemergence of the SARS-CoV is still considered a
potential pandemic risk and potentially new strains of SARS
could be more severe than that found from the 2003 outbreak.
Since 2003, two additional human coronaviruses, NL63 and
HKU1, have been identified in patients around the world, and
INTRODUCTION
■
Coronaviruses (CoV) are enveloped, large plus-strand RNA
viruses that cause medical disorders such as the common cold,
lower respiratory tract infections, and diarrhea.1 The first
characterized human CoV strains, 229E and OC43, were
identified and studied extensively from 1965 to the mid-1980s.2
In 2003, the novel SARS-CoV was identified3,4 as the etiological
agent of the global pandemic of severe acute respiratory
syndrome (SARS), an atypical pneumonia that led to
progressive respiratory failure in over 8000 individuals and
800 deaths by July of that year.5 The death rate of
approximately 10% for the SARS virus and its ability to spread
Received: October 25, 2012
© XXXX American Chemical Society
A
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
Figure 1. Representative first generation peptidic 3CLpro inhibitors 1−7 highlighting reactive warhead groups (red) and side chain residues (P1
blue).
Figure 2. Representative second generation nonpeptidic 3CLpro inhibitors highlighting potential warhead groups (red).
the viruses have been characterized and found to be
significantly less lethal than SARS-CoV.6−8 Most recently, a
new SARS-like virus, called HCoV-EMC, has been identified in
at least two individuals, one of whom died.9 Sequence analysis
of HCoV-EMC indicates that this virus is more closely related
to bat coronaviruses than to SARS-CoV. Therefore, the
possibility of a future SARS-like pandemic remains possible,
and to date, there are still no vaccines or antiviral agents
available to prevent or treat SARS-like infections.
The SARS-CoV genome encodes a large polyprotein that is
proteolytically processed by two cysteine proteases including
the 3C-chymotrypsin-like protease (3CLpro) and the papain-
like protease (PLpro). 3CLpro is essential for proteolytic
processing at 11 different cleavage sites within the coronavirus
polyprotein and is thus vital for viral replication.10 The 3CLpro
enzyme exists primarily as a dimer in solution, and the dimer
has been confirmed to be the active species for the enzyme
reaction.11 The cloning and expression of recombinant SARS
3CLpro,12 along with studies showing that 3CLpro is essential
for the viral life cycle,13 support a role for 3CLpro as an
important pathogenic component of SARS-CoV and therefore
a viable target for antiviral drug development.
The SARS-CoV 3CLpro has three domains: I (residues 8−
101), II (residues 102−184), and III (residues 201−301).
Domains I and II, which contain the active site region, are β-
barrel domains, and domain III is an α-helical domain. The
active site contains a catalytic dyad consisting of a cysteine
residue (Cys-145) that acts as a nucleophile and a histidine
residue (His-41) that acts as the general acid−base. Optimized
octapeptide-based inhibitors using mutational and CoMFA
models have been reported,14 and more recently, a systematic
saturation mutagenesis study was conducted at the P5 through
P3′ positions of the substrate.15 These results demonstrate a
strong structure−activity relationship between 3CLpro and its
substrate and have provided a basis for peptidomimetic
inhibitor design. X-ray structures of the SARS-CoV 3CLpro
B
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
enzyme bound to hexapeptidyl chloromethyl ketone inhibitors
were first reported,16−18 and numerous peptidic structures now
exist in the context of targeted antiviral drug design.19−24 These
first generation protease inhibitors maintain a peptidic nature,
often five residues in length, and bear a reactive warhead group
at the terminus that forms a covalent interaction with Cys-145
(Figure 1, 1−7). Reactive “warhead” groups for 3CLpro have
included aldehydes, epoxy-ketones, halo-methyl ketones,
trifluoromethyl ketones, and a number of examples of Michael
acceptors.19−25 These inhibitors often first form a noncovalent
interaction complex with the enzyme, positioning the warhead
in close proximity to the catalytic cysteine. Attack of the
thiolate anion of the catalytic cysteine onto the reactive atom of
the warhead leads to formation of the covalent adduct,
inactivating the enzyme. One of these compounds, TG-
0205221 (5), reacts with SARS 3CLpro with a reported Ki
value of ∼60 nM.22
These first generation inhibitors achieved submicromolar
activity and provided valuable insights into further structure-
based inhibitor design, quickly leading to nonpeptidic, warhead-
based small molecule inhibitors (Figure 2, 8−11).19,26−35
Efforts utilizing virtual screening approaches also proved
successful leading to nonpeptidic inhibitors (e.g., 12 and
13).32,33 One of the early compounds disclosed bearing a
cinnamyl amide, cinanserin (Figure 2, 8), has a reported IC50
value of ∼5 μM.26 Low molecular weight nonpeptide inhibitors
bearing reactive esters (9−10b)27−29 and ketone moieties
(11a,b)30,31 have demonstrated moderate to good micromolar
inhibition and in the case of pyridyl ester 10b29 achieved
inhibition in a cell-based assay below 10 μM.
The utility and development of using covalently bound
inhibitors can unfortunately be limited due to their potential for
off-target side effects and toxicity.36 Despite the fact that there
are currently 39 commercially available therapeutics that act
through covalent-modification mechanisms, none of these
target cysteine proteases.36 The fact that all of the protease
classes (serine, threonine, aspartyl, and metallo), with the
exception of cysteine, have been targeted by marketed
therapeutics suggests that advancing covalent cysteine-protease
inhibitors to market may have unique challenges.37 Therefore,
researchers are now focusing more attention on the
identification of noncovalent inhibitors. Legitimate noncovalent
inhibitors described to date have been limited to high molecular
weight peptidomimetics (MW > 800 amu) with low ligand
efficiency38,39 and have included known protease drugs
originally developed for HIV protease.40 In an effort to identify
small molecule inhibitors of the SARS 3CLpro that inhibit via a
noncovalent mechanism and possess low micromolar potency
and good cell permeability, a screen was conducted in 2009
against the NIH molecular libraries sample collection
(∼293000 compounds) in collaboration with the Mesecar
laboratory and the Scripps Research Institute Molecular
Screening Center (SRIMSC) through the molecular libraries
program center network (MLPCN).41 Herein we describe the
results of this screening campaign and the prosecution of an
optimization effort at the Vanderbilt Specialized Chemistry
Center (VSCC) around a class of 2-(N-arylamido)-2-(pyridin-
3-yl) acetamide inhibitors of moderate molecular weight. In
addition, from these collaborative efforts and with the aid of X-
ray crystallography, we report the details of the molecular
interaction of 3CLpro inhibitor 16-(R) with the active site of
3CLpro and further describe the physicochemical and ancillary
properties of 16-(R).
RESULTS AND DISCUSSION
■
SARS-CoV 3CL Protease Construct Used in Assays and
Lack of Inhibition by Cinanserin. The 3CLpro enzyme, also
known as nonstructural protein 5 (nsp5), is liberated from
coronavirus polyproteins by self-cleavage at its N-terminal
(nsp4/5) and C-terminal (nsp5/6) cleavage sites. Although the
autocatalytic mechanism is still being elucidated, current studies
suggest that it involves an initial dimerization event between
two unreleased nsp5s within the polyprotein followed by a
series of catalytic steps that liberate a fully active, dimeric
enzyme that can then proceed to processing the remaining 9
cleavage sites of the polyprotein.42 The SARS-CoV 3CLpro is
highly active as a dimer and is essentially inactive as a
monomer.43 The addition of affinity tags or additional amino
acids to the N- and C-termini of 3CLpro is found to
substantially increase the dimer dissociation constant (Kd)
and dramatically decrease the enzymatic activity of the
enzyme.42 Therefore, we expressed and purified SARS-CoV
3CLpro from a newly designed expression construct that
produces the authentic 3CLpro dimer that would be generated
in a virus infected cell. The enzyme was purified by a multistep
chromatographic procedure and was found to be highly active.
Because the compound cinanserin was reported to be a
highly effective noncovalent inhibitor of SARS-CoV and
HCoV-229E 3CLpros, with IC50 values of 5 μM against each
enzyme,26 we sought to use this compound as a control
inhibitor to calculate Z′-factors during our high-throughput
screening of compound libraries. We tested the ability of
cinanserin to inhibit our authentic version of SARS-CoV
3CLpro at a concentration of 100 μM, and surprisingly, we
found no inhibition of the enzyme. Next, we tested the ability
of cinanserin to inhibit the 3CLpro enzymes from the human
coronavirus HKU1 and the mouse coronavirus MHV. Once
again, we found no inhibition of these 3CL proteases at a
cinanserin concentration of 100 μM.
Since our kinetic inhibition results stand in contrast to those
of Chen and co-workers,26 we sought an explanation for this
large discrepancy in potency. Upon closer examination of the
reported methods used to determine the IC50 values for
cinanserin, we found that the 3CLpro expression construct
utilized by Chen and co-workers incorporated a (His)6-affinity
tag at the N-terminus that extended it by an additional 14
residues.44 The N-terminal affinity tag was never removed from
the purified 3CLpro enzymes prior to their kinetic studies. As
described above, the addition of N-terminal or C-terminal
residues to SARS 3CLpro is known to have a dramatic effect in
increasing the dissociation constant for dimerization of the
enzyme, as well as decreasing the enzymatic activity of the
enzyme.43 Therefore, cinanserin may be inhibiting a non-
dimeric form of the enzyme. Another possible explanation is
that Triton X-100 was not included in the assay buffer to
remove potential promiscuous inhibition caused by nonspecific
aggregation of the protein by the compounds.45 We tested
cinanserin for inhibition of SARS-CoV, HKU1, and MHV
3CLpro at a concentration of 100 μM cinanserin in both the
presence and absence of 0.01% Triton X-100 and found no
inhibition of the enzymes in either case. Ultimately, we were
unable to use cinanserin as a control inhibitor since no
inhibition of SARS-CoV, HKU1, or MHV 3CL proteases was
observed. We therefore used compound 10a (Figure 2), a
covalent modifier, as a positive control compound.
C
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
Figure 3. (left) Hit furyl amide 14 (SID49730186); (right) inhibition concentration curve for 3CLpro (gray squares) and PLpro (black squares) and
14.
Scheme 1. Ugi Strategy and Monomers Used To Prepare Library 15 Holding R4 as t-Butyl Isocyanide
Screening Campaign and Lead Identification at the
SRIMSC. High-throughput screening was conducted by
evaluating the inhibition of the 3CLpro-mediated peptide
cleavage event using a novel FRET-based substrate (Pubchem:
AID 1859). We utilized a number of key assay features in the
screening campaign that have significant advantages over
previous HTS campaigns against the 3CL enzyme.46 First, we
utilized a SARS-CoV 3CLpro construct that consisted of the
native sequence of the enzyme that represents the in vivo
postproteolytic form of the enzyme. As discussed above, our
version of the enzyme does not contain tags or excess amino
acids that are known to drastically reduce catalytic activity of
the enzyme.43 Second, we maintained a high concentration of
fresh reducing agent in the primary assays, which helped to
minimize but did not eliminate covalent compounds as primary
leads. Finally, we utilized a highly fluorescent FRET-based
3CLpro peptide substrate composed of a HiLyte fluor 488
fluorescent label attached at the N-terminus and a QXL520
quencher dye attached to the C-terminus. This substrate allows
for excitation in the spectral region of 488 nm that helps to
eliminate spectral overlap with the compounds in the screen.
Moreover, the high fluorescence quantum yield of the
fluorescent probe and sufficiently low turnover number of the
enzyme yields a highly sensitive assay that is amenable to
screening in 1536 plate format with low (≪Km) substrate
concentrations.
The primary screen of the molecular libraries small molecule
repository (∼293,000 compounds at the time of screen) was
conducted using a 6 μM concentration of each compound. The
primary screen produced 406 hits with greater than 12.25%
inhibition. An excellent Z′ score of 0.92 and a relatively low hit-
rate of 0.14% were observed. Among the 406 hits, 380 were
available for reorder and were tested in a confirmation screen
(singles at 10 μM). This second screen produced 136 active
compounds with greater than 12.25% inhibition. A subsequent
dose−response testing of 101 compounds provided 44 actives
with IC50 values below 10 μM. A number of these actives were
then counter-screened against the SARS-CoV papain-like
D
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
Figure 4. Selected SAR highlights from first round Ugi library.
protease, PLpro, which is also a potential target since it too is
vital for SARS-CoV maturation.46,47 In general, the majority of
IC50 values were substantially greater than 10 μM against PLpro
suggesting moderate to good selectivity for 3CLpro inhibition.
Prior to initiation of the chemistry phase of the project,
SRIMSC performed structural clustering analysis of the 101
confirmed actives. Several interesting scaffold clusters and a
handful of singletons were identified from this analysis. A
dipeptide class, represented by hit 14 (Figure 3, SID49730186),
was one of two analogues with an IC50 below 10 μM. This furyl
amide series was of particular interest due to its starting
potency, modular nature, structural properties, and absence of
reactive functionality found within typical covalent modifiers.
Probe Optimization of Furyl Amide 14. Within the furyl
scaffold, an initial 80 compound library array 15 was designed
based upon HTS data using an Ugi MCC (multicomponent
condensation) strategy (Scheme 1).48,49
In the initial Ugi array, the isocyanide was held constant to
afford a tert-butyl group at R4. The α-aryl substituent R3 was
maintained either as a 3-pyridyl, as found in the original hit 14,
or as a 2-thienyl, which was also identified as a tolerable group
in another closely related dipeptide cluster from HTS. Five
monomers were selected for the R2 amine group to examine
modifications of the aryl, and a cyclopropyl was included as a
potential aryl replacement as a means to reduce MW and
overall lipophilicity. For the R1 carboxylic acid component,
eight monomers were chosen focusing exclusively on
substituted aromatics and heteroaromotics. As part of the R1
group scan, a furan-3-carboxylic acid was included as a control
for SAR comparisons relative to 14. All 80 compounds were
successfully prepared and submitted for testing.
replacement of the lipophilic N-aryl R2 group with either a
cyclopropyl group or a 4-fluoro phenyl derivative (Figure 4, 18
and 19) were deleterious for inhibition, indicating the
importance of steric bulk for optimal interaction within this
putative subpocket of the enzyme. The 3-thienyl congener 20, a
direct analogue of 16, resulted in a complete loss of inhibition
activity.
Concurrent with synthetic plans to prepare a second
generation Ugi library, SARS-CoV 3CLpro crystals suitable
for X-ray diffraction and analysis were obtained with inhibitor
16 bound to 3CLpro.50 The electron density associated with
inhibitor 16 is clearly resolved and allowed for accurate
refinement of its position (Figure 6). The binding orientation
of 16 is overall similar to known covalent peptidomimetic
inhibitors, with inhibitor 16 preferentially occupying the S3−S1′
subpockets of the 3CLpro enzyme as the R enantiomer
(Figures 5−7).21 In this orientation, the tert-butyl amide
occupies the S3 pocket, the tert-butylanilido group occupies a
deep S2 pocket, the 3-pyridyl group occupies the S1, and the
furyl amide acts as a P1′ group. For comparison, the
Disappointingly, only two Ugi library analogues displayed
inhibition levels greater than 50% at 100 μM and subsequently
were determined to have IC50 values less than 50 μM. Notably,
these active analogues were exclusively within the 3-pyridyl
subseries (Figure 4, 16 and 17). Within the 3-pyridyl series,
Figure 5. Schematic of enzyme pockets occupied by 16 and 4.
E
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
Figure 6. SARS-CoV 3CLpro active site with bound inhibitor 16. (left) Wall-eye stereoview of the Fo− Fc electron density omit map (3σ)
surrounding inhibitor 16. (right) Solvent-accessible surface view of 16-3CLpro complex (PDB code 3V3M, PubChem SID87915542).
mechanism-based covalent inhibitor 4 (PDB code 2ALV) and
its occupied subpockets are represented schematically in Figure
5 relative to inhibitor 16.21 In addition to the S3−S1′ pockets
occupied by 16, 4 occupies the S4 pocket, thus relative to 4 the
MW of 16 is reduced by over 100 amu and furthermore 16
lacks a reactive warhead.
An electron density map and a solvent-accessible surface
depiction of 16 bound to 3CLpro are shown in Figure 6. A
stereoview of the inhibitor-bound structure and associated
interactions is also shown in Figure 7. Interestingly, the 3-
chemical library focusing exclusively on the P1′ group holding
the P1−P3 groups constant. Results from this campaign are
summarized in Figure 8 (21−48).
Replacement with five-membered π-excessive heterocycles
proved most successful with 22, 27, and 31 having IC50’s ∼50
μM and below. A fully saturated tetrahydrofuran (32) and a
select set of acyclic analogues were >10-fold less active with
IC50’s > 50 μM. Substitution on the furan ring negatively
impacted activity (21, 26) and although replacement of the
Figure 7. X-ray crystal structure of 16 (capped sticks in green carbon)
with SARS 3CLpro in wall-eye stereoview. Hydrogen bonds between
inhibitor and 3CLpro are shown as black dotted lines.
pyridyl ring nitrogen serves as a hydrogen bond acceptor within
the S1-subpocket engaging His-163 with a N−N interatomic
distance of 2.8 Å. A similar hydrogen-bond interaction with
His-163 engaged is retained in other 3CLpro crystal
structures.21 The furan ring oxygen and the amide carbonyl
oxygen have a bifurcated interaction with the backbone NH of
Gly-143. Although the distance to the amide carbonyl is 0.5 Å
closer to Gly-143 and appears to be a hydrogen bond, based
upon distance (CO to NH = 2.9 Å), the geometry is not
ideal. In fact, the NH of Gly-143 is nearly coplanar with both
oxygen atoms. On the floor of the S1′ pocket, the catalytic Cys-
145 is positioned beneath both the amide carbonyl carbon and
the furan oxygen at a distance of 3.5 Å. With this rather unique
furyl amide interaction within the context of the catalytic
residues and backbone Gly-143 interaction, we set out to
understand this interaction further by preparing a second
Figure 8. Twenty-eight-membered P1′ Ugi library (21−48) and
subsequent exploration of five-membered azole and furan analogues
(49−52). Inhibitor data indicated for compounds with 49% or greater
inhibition at 100 μM test concentration.
F
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
furan oxygen atom with a larger sulfur atom in the related
thiophene (27) was weakly tolerated (10-fold loss), the related
pyrrole (37) heterocycle was completely inactive. The nearly
equipotent inhibition by the imidazole 31 (SID93616598)
however was encouraging, and thus a smaller subset of
analogues was prepared to complete the survey of five-
membered heterocycles (49−52). This effort identified 2-
oxazolyl analogue 49 (SID99350507) with similar potency to
the 4-oxazolyl isomer 22. Interestingly, in contrast to the 2-
methyl furyl derivative 21, the 2-chloro-substituted furyl
congener 50 (SID99350505) was nearly equipotent to 16
with an IC50 of 5.2 μM. SAR around imidazole 31 proved steep
as the N-methyl C(4) substituted analogue 52 was >10-fold less
active and addition of a methylene spacer (51) was deleterious
for inhibition.
replace the 3-pyridyl P1 with 1,2-diazoles (58, 59), 1,2,3-
triazoles (60), or 1,3-diazoles (61) were also unsuccessful in
identifying compounds with improved inhibition.
We next turned to chiral stationary phase supercritical fluid
chromatography (SFC) to separate and isolate the single
enantiomers of 16 (Figure 9). Highly specific inhibition was
found for single stereoisomer 16-(R) with an IC50 of 1.5 0.3
μM, which was identified as the first eluting peak from chiral
SFC. In addition, inhibitor 16-(R) was found to specifically
inhibit 3CLpro versus PLpro. Inhibitor 16-(R) was sub-
sequently declared MLPCN probe ML188.41 Inhibitor 16-(R)
was inferred as the R stereoisomer based upon the absolute
configuration observed in the electron density map of the X-ray
structure of the 16-3CLpro complex, and it was found to rotate
plane polarized light in the positive direction. Finally, the
mechanism of inhibition of SARS 3CLpro by 16-(R) was
determined to be competitive based on a double-reciprocal plot
of the initial rate of the SARS 3CLpro catalyzed reaction versus
variable concentrations of substrate and fixed, variable
concentrations of 16-(R) (see Figure 2, Supporting Informa-
tion). The resulting Ki value was determined to be 1.6 0.26
μM, which is equivalent to its IC50 value and is expected since
the IC50 values for the inhibitors are determined at a substrate
concentration that is significantly lower than the Km value.
SARS-CoV Antiviral Activity of 16-(R). The potency of
16-(R) against SARS-CoV 3CLpro was deemed sufficient to
determine the antiviral potency of the compound against SARS-
CoV Urbani infected Vero E6 cells. Using our established
antiviral assay and BSL3 protocols, we generated a dose−
response curve of 16-(R) against mock-infected and SARS-CoV
infected cells, and the results are shown in Figure 10.47
A fit of the data presented in Figure 10 yields an antiviral
EC50 value of 12.9 0.7 μM. A second experiment, performed
one month later, yielded an EC50 value of 13.4 1.0 μM. The
two independent experiments demonstrate that the resulting
noncovalent inhibitor, 16-(R), can effectively inhibit SARS-
CoV replication in cell culture.
A subsequent survey of P1 replacements was performed in
order to identify alternate hydrogen bond acceptor groups that
might engage His-163, while retaining the 2-furyl amide P1′
group (Table 1).
Table 1. Focused P1 Group Heterocyclic Library (53−61)
We searched the literature for other noncovalent inhibitors
against SARS-CoV 3CLpro that also have antiviral data
associated with the compound. The compound cinanserin is
reported to have antiviral activity.26 In that report, SARS-CoV
infected Vero cells were treated with 50 μg/mL (134 μM)
cinanserin. The authors conducted an RNA quantitation assay
of the cell culture media and reported a 3 log reduction and
indicate that this reduction correlates with the titer of infectious
particles. The authors also did a control cytotoxicity assay and
reported that the cytotoxic concentration that gives 50%
reduction (CC50) is 31 μM and the CC90 is 66 μM. Given the
fact that under these high cinanserin concentrations (134 μM)
the majority of Vero cells (>90%) are likely killed by cinanserin,
interpretation of the antiviral data in these studies is deemed
ambiguous.
#
IC50 values are average of two independent runs using triplicate
concentrations; “Inactive” defined as %inhibtion <15% at 100 μM, CV
We next compared the EC50 of 16-(R) value to another
noncovalent compound tested against SARS-CoV infected cells
that targets the SARS-CoV papain-like protease (PLpro)
known as GRL0617.47 Compound GRL0617 has an IC50
against the PLpro enzyme of 600 nM and an EC50 value of
14.5 μM against SARS infected Vero E6 cells.47 We next
compared the EC50/IC50 ratios of the noncovalent compounds,
16-(R) and GRL0617, which are ∼8.7 and ∼24.1, respectively.
This ratio can help guide compound design in terms of
estimating what value of an IC50 needs to be achieved in order
to achieve a pharmacologically relevant effect. Therefore, we
<0.3.
Among the various P1 replacements examined (53−61)
pyridazine (53) and pyrazine (54) were well tolerated, although
no improvement was found over lead compound 16. More
dramatic modifications around the pyridyl ring were clearly
limited for reasons consistent with the inhibitor bound X-ray
structure because both the 4- and 2-pyridyl analogues were
either weak inhibitors (56) or inactive (57) and addition of a 2-
methyl in pyridyl analogue 55 was not permitted. Attempts to
G
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
Figure 9. Preparative chiral separation of 16 and identification of 16-(R).
several key interactions crucial for activity; in particular, a
hydrogen bonding interaction between the inhibitor 3-pyridyl
ring nitrogen and the active site His-163 side-chain located
within the S1-subpocket. Probe 16-(R) (ML188) is a modest
molecular weight SARS-CoV 3CLpro inhibitor with demon-
strated antiviral activity and a noncovalent mechanism of action
and thus provides the opportunity to facilitate further structure-
based design and inhibitor refinement in the quest for potential
novel anti-SARS CoV therapies. Collaborative efforts in these
laboratories continue toward the identification of submicromo-
lar 3CLpro inhibitors with optimal properties for antiviral
activity and potential testing in animal models. ML188 is an
MLPCN probe and is freely available upon request.
Figure 10. Vero E6 cells were mock-infected (blue diamonds) or
infected with SARS-CoV (red squares) for 1 h prior to the addition of
the antiviral compound 16-(R). At 48 h postinfection, cell viability was
determined using Cell Titer-Glo luminescent cell viability assay
(Promega). The error bars represent the standard deviation of
triplicate samples. Experiments were performed in duplicate on
separate days.
EXPERIMENTAL SECTION
■
General. All NMR spectra were recorded on a Bruker 400 and 600
1
MHz instrument. H chemical shifts are reported in δ values in ppm
downfield from TMS as the internal standard in d3-MeOH or CDCl3.
Data are reported as follows: chemical shift, multiplicity (s = singlet, d
= doublet, t = triplet, q = quartet, br = broad, m = multiplet),
integration, coupling constant (Hz). Low-resolution mass spectra were
obtained on an Agilent 1200 series 6130 mass spectrometer. High-
resolution mass spectra were recorded on a Waters Q-TOF API-US.
Analytical thin layer chromatography was performed on Analtech silica
gel GF 250 μm plates. Analytical HPLC was performed on an HP1100
with UV detection at 214 and 254 nm along with ELSD detection, LC-
MS (J-Sphere80-C18, 3.0 mm × 50 mm, using either a 1.1 or 3.1 min
gradient, 5%[0.05%TFA/CH3CN]/95%[0.05%TFA/H2O] to
100%[0.05%TFA/CH3CN]. Preparative RP-HPLC purification was
performed on a custom HP1100 automated purification system with
collection triggered by mass detection or using a Gilson Inc.
preparative UV-based system using a Phenomenex Luna C18 column
(50 mm × 30 mm I.D., 5 μm) with an acetonitrile (unmodified)−
water (0.1% TFA) custom gradient. Normal-phase silica gel
preparative purification was performed using an automated Combi-
flash companion from ISCO. Solvents for extraction, washing, and
chromatography were HPLC grade. All reagents were purchased from
Aldrich Chemical Co. and were used without purification. All polymer-
supported reagents were purchased from Argonaut Technologies and
Biotage.
General Procedure for 4CC-Ugi Reaction in Library Format.
To a series of 13 mm × 100 mm screw top glass tubes fitted with a
magnetic stir bar equimolar amounts (0.08 mmol) of carboxaldehyde,
amine, and carboxylic acid were combined in methanol (0.2 M, 1.5
mL) and subsequently treated with tert-butylisocyanide (0.08 mmol).
The mixture was stirred for 16 h at ambient temperature and then
concentrated under a stream of nitrogen in a well-ventilated hood. The
crude mixtures were reconstituted in MeOH, treated with Argoresin
MP-Trisamine (Biotage Inc.) scavenger for 2 h and applied to a Celite
pad using a manifold fitted with polypropylene filter tubes capable of
compared these values to the most potent covalent 3CLpro
inhibitor identified to date, TG-0205221 (5).22 This compound
has an EC50/Ki value of 0.6 μM/0.052 μM or ∼11.5. Thus,
noncovalent and covalent inhibitors of 3CLpro can achieve
similar antiviral effects.
Based upon the structural information, excellent 3CL
protease inhibition activity, and SARS-CoV Ubani antiviral
activity, 16-(R) was elected as a first in class probe candidate
from the furyl amide series. Probe 16-(R) was found to be
highly selective for 3CLpro versus PLpro, and in a Ricerca lead-
profiling screen51 against 68 discrete GPCRs, ion channels and
transporters, no significant activity was found (<50% at 10
μM). In PBS buffer at neutral pH, probe 16-(R) was found to
have excellent aqueous solubility up to 95 μg/mL or 219 μM.
Extended characterization of probe inhibitor 16-(R) and
analogues against other cysteine proteases and in SARS-CoV
infected cells as well as DMPK studies to assess metabolic
stability and plasma protein binding are ongoing.
CONCLUSIONS
■
In summary, we have described the optimization and molecular
interaction details for a potent, noncovalent inhibitor of SARS-
CoV 3CLpro identified through the MLPCN initiative. A four-
component Ugi reaction was utilized to rapidly generate SAR
and optimize potency focusing on the S1′, S1, and S2 binding
pockets. X-ray analysis of the 3CLpro−16-(R) complex reveals
H
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
filtering 24 samples in parallel. The filtrates were purified directly using
an automated mass-guided RP-HPLC, and product containing
fractions were concentrated to give final products >95% purity as
129.6, 129.0, 126.7, 125.8, 125.1, 116.7, 111.1, 61.6, 51.4, 34.6, 31.3,
28.6. HRMS (ES+, M + H) calcd for C25H31N2O3S 439.2055, found
439.2057.
1
judged by LC-MS (215 nm and ELSD) and H NMR (representative
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
3-yl)ethyl)oxazole-5-carboxamide, 22. 1H NMR (400 MHz, CDCl3)
δ 8.48 (2H, s), 7.84 (1H, s), 7.48 (1H, d, J = 7.9 Hz), 7.28 (2H, m),
7.08 (1H, m), 6.06 (1H, s), 5.85 (1H, bs), 5.70 (1H, s), 5.30 (1H, s)
1.37 (9H, s), 1.27 (9H, s). 13C NMR (100 MHz, CDCl3) δ 167.3,
157.7, 152.8, 152.1, 151.2, 149.3, 144.1, 137.7, 134.9, 131.1, 130.3,
129.9, 125.9, 122.7, 62.9, 51.5, 34.4, 30.9, 28.3. HRMS (ES+, M + H)
calcd for C25H31N4O3 435.2396, found 435.2397.
library members >10%). All final library array product characterization
data, 1H NMR spectra, and SARS-3CLpro % inhibition at 100 μM can
be found in Supporting Information.
Analogues 21−48 and 49−61 were prepared in an analogous
manner and purified by Gilson Inc. preparative UV-based RP-HPLC.
1
Chromatographic, LC-MS data, and representative H and 13C NMR
spectra for these remaining analogues can be found in Supporting
Information. 1H NMR data for 20% of these libraries have been
provided.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
3-yl)ethyl)thiophene-2-carboxamide, 27. 1H NMR (400 MHz,
CDCl3) δ 8.47 (1H, s), 8.44 (1H, d, J = 4.0 Hz), 7.48 (1H, d, J =
8.0 Hz), 7.29 (1H, dd, J = 4.8, 0.9 Hz), 7.23 (2H, d, J = 8.3 Hz), 7.05
(1H, dd, J = 7.9, 4.8 Hz), 7.01 (1H, bs), 6.75 (2H, m), 6.29 (1H, bs),
6.14 (1H, s), 1.36 (9H, s), 1.26 (9H, s). 13C NMR (100 MHz, CDCl3)
δ 167.9, 162.9, 152.6, 151.4, 149.4, 138.0, 137.5, 136.5, 133.1, 131.6,
130.6, 130.5, 126.7, 126.1, 122.7, 64.1, 51.7, 34.6, 31.2, 28.6. HRMS
(ES+, M + H) calcd for C26H32N3O2S 450.2215, found 450.2213.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
Preparation of (R)-N-(4-(tert-butyl)phenyl)-N-(2-(tert-butyla-
mino)-2-oxo-1-(pyridin-3-yl)ethyl)furan-2-carboxamide (16-
(R), ML188). To a 20 mL scintillation, equimolar amounts (0.5
mmol) of pyridine-3-carboxaldehyde, 4-tert-butylaniline, and furan-2-
carboxylic acid were combined in methanol (0.2M, 2.5 mL) and
treated with tert-butylisocyanide (0.5 mmol). The mixture was stirred
for 16 h at ambient temperature and then concentrated and applied as
a DCM solution to a silica column (12 g) and purified over a gradient
of 0 to 100% EtOAc in hexanes. The racemic product was obtained as
a light yellow solid (198 mg, 91%): LC-MS (>98%) m/z = 434 [M +
H]. Separation of enantiomers was accomplished using supercritical
fluid chromatography. The column was an IA (UV 250 nm, 10 mm ×
250 mm, Chiral Technologies), eluent 6% MeOH in CO2. The desired
peak as confirmed by the primary assay was identified as the first
1
3-yl)ethyl)-1H-imidazole-4-carboxamide, 31. H NMR (600 MHz,
CDCl3) δ 11.666 (1H, bs), 8.47 (1H, d, J = 1.9 Hz), 8.41 (1H, dd, J =
3.2, 1.4 Hz), 7.59 (2H, s), 7.39 (1H, d, J = 5.3 Hz), 7.22 (3H, bs), 7.01
(1H, dd, J = 5.3, 4.8 Hz), 6.32 (1H, bs), 6.20 (1H, s), 5.43 (1H, bs),
1.24 (9H, s), 1.23 (9H, s). 13C NMR (150 MHz, CDCl3) δ 167.8,
161.1, 152.9, 151.4, 149.5, 137.9, 137.3, 135.6, 133.2, 130.5, 126.2,
125.0, 122.8, 63.5, 51.6, 34.6, 31.2, 28.5. HRMS (ES+, M + H) calcd
for C25H32N5O2 434.2556, found 434.2555.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
3-yl)ethyl)-2-methoxybenzamide, 33. 1H NMR (400 MHz, CD3OD)
δ 8.72 (1H, bs), 8.60 (1H, bs), 8.24 (1H, bs), 7.73 (2H, bs), 7.30 (1H,
d, J = 7.4 Hz), 7.22 (1H, t, J = 7.4 Hz), 7.11 (2H, d, J = 8.4 Hz), 7.00
(2H, d, J = 8.3 Hz), 8.87 (1H, t, J = 7.4 Hz), 6.76 (1H, d, J = 8.2 Hz),
6.25 (1H, s), 3.68 (3H, s), 1.29 (9H, s), 1.15 (9H, s). LC-MS (M + H)
= 474.2.
eluting peak, retention time = 2.91 min (CID 46897844): [α]D
=
+38.9 (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 8.51 (1H, d, J
= 2), 8.49 (1H, dd, J = 4.8, 2), 7.53 (1H, dt, J = 8, 2), 7.41 (1H, d, J =
1), 7.29 (2H, d, J = 6.6), 7.23 (2H, d, J = 6.6), 7.09 (1H, dd, J = 8, 4.8),
6.18 (1H, dd, J = 3.6, 2), 6.12 (1H, s), 5.41 (1H, d, J = 3.6), 1.40 (9H,
s), 1.28 (9H, s). 13C NMR (400 MHz, CDCl3) δ 167.7, 159.5, 152.4,
151.3, 149.4, 146.1, 144.9, 138.1, 136.4, 130.4, 130.1, 126.0, 122.7,
117.0, 111.1, 63.6, 51.7, 34.6, 31.2, 28.6. HRMS (ESI, M + H) calcd
for C26H32N3O3 434.2440, found 434.2444.
N-(2-(tert-Butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)-N-(4-
isopropylphenyl)furan-2-carboxamide, 17. 1H NMR (400 MHz,
CDCl3) δ 8.46 (2H, m), 8.49 (1H, d, J = 7.9 Hz), 7.38 (1H, s), 7.07
(3H, m), 6.98 (2H, bs), 6.15 (2H, m), 6.10 (1H, s), 5.38 (1H, d, J =
3.6 Hz), 2.87 (1 H, p, J = 6.9 Hz), 1.37 (9H, s), 1.20 (6H, d). 13C
NMR (100 MHz, CDCl3) δ 167.8, 159.5, 151.4, 150.0, 149.4, 146.1,
144.8, 138.0, 136.6, 130.5, 130.4, 127.0, 122.7, 117.0, 111.1, 63.5, 51.6,
33.6, 28.5, 23.8, 23.7. HRMS (ES+, M + H) calcd for C25H30N3O3
420.2287, found 420.2290.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
3-yl)ethyl)isonicotinamide, 35. 1H NMR (400 MHz, CD3OD) δ 8.57
(1H, s), 8.50 (3H, m), 7.98 (1H, m), 7.57 (2H, m), 7.51 (1H, m), 7.12
(4H, m), 6.28 (1H, s), 1.34 (9H, s), 1.14 (9H, s). LC-MS (M + H) =
445.2.
N-(tert-butyl)-2-(N-(4-(tert-butyl)phenyl)-2-hydroxyacetamido)-
2-(pyridin-3-yl)acetamide, 40. 1H NMR (400 MHz, CD3OD) δ 8.50
(2H, m), 7.99 (1H, d, J = 6.5 Hz), 7.55 (1H, m), 7.33 (2H, d, J = 9.1
Hz), 7.15 (2H, bs), 6.12 (1H, s), 3.83 (1H, d, J = 3.0 Hz), 1.29 (9H,
s), 1.26 (9H, s). LC-MS (M + H) = 398.2.
N-(2-(tert-Butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)-N-cyclopro-
1
pylfuran-2-carboxamide, 18. H NMR (400 MHz, CDCl3) δ 8.68
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
1
3-yl)ethyl)-3-hydroxybenzamide, 44. H NMR (400 MHz, CD3OD)
(1H, s), 8.57 (1H, d, J = 4.0 Hz), 7.97 (1H, d, J = 7.9), 7.53 (1H, s),
7.32 (1H, dd, J = 7.7, 4.8), 7.10 (1H, d, J = 3.4 Hz), 6.57 (1H, s), 6.51
(1H, dd, J = 3.4, 1.6 Hz), 5.66 (1H, s), 2.90 (1H, m), 1.36 (9H, s),
0.99 (1H, m), 0.80 (m, 1H), 0.68 (m, 2H). 13C NMR (100 MHz,
CDCl3) δ 168.3, 162.4, 150.5, 148.9, 147.2, 144.5, 137.1, 131.1, 122.8,
117.1, 111.2, 64.7, 51.1, 31.2, 28.2, 10.4, 9.5. HRMS (ES+, M + H)
calcd for C19H24N3O3 342.1818, found 342.1815.
N-(2-(tert-Butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)-N-(4-
fluorophenyl)furan-2-carboxamide, 19. 1H NMR (400 MHz,
CDCl3) δ 8.41 (1H, d, J = 4.0 Hz), 8.37 (1H, s), 7.43 (1H, d, J =
8.0), 7.29 (1H, s), 7.05 (2H, dd, J = 7.8, 4.8), 6.85 (2H, m), 6.29 (1H,
s), 6.15 (1H, s), 6.13 (1H, dd, J = 3.5, 1.6 Hz), 5.55 (1H, d, J = 3.6
Hz), 5.24 (s, 1H), 1.30 (9H, s). 13C NMR (100 MHz, CDCl3) δ 167.8,
162.5 (d, J = 248), 159.3, 151.3, 149.5, 146.1, 144.9, 137.8, 134.9 (d, J
= 3.1 Hz), 132.9 (d, J = 8.6 Hz), 130.3, 123.0, 117.2, 115.8 (d, J = 22.4
Hz), 111.1, 62.8, 51.7, 28.5. HRMS (ES+, M + H) calcd for
C22H23N3O3F 396.1723, found 396.1725.
δ 8.63 (1H, bs), 8.56 (1H, bs), 8.16 (1H, bs), 7.66 (1H, m), 7.14 (2H,
d, J = 8.8 Hz), 7.02 (2H, d, J = 8.1 Hz), 6.97 (1H, t, J = 7.9 Hz), 6.78
(1H, s), 6.74 (1H, d, J = 7.7 Hz), 6.66 (1H, dd, J = 8.2, 1.5 Hz), 6.26
(1H, s), 1.29 (9H, s), 1.17 (9H, s). LC-MS (M + H) = 460.2.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
3-yl)ethyl)pyrimidine-2-carboxamide, 45. 1H NMR (400 MHz,
CD3OD) δ 8.65 (1H, d, J = 11.8 Hz), 8.54 (1H, d, J = 5.2 Hz),
8.43 (1H, s), 8.38 (1H, s), 8.10 (1H, d, J = 6.8 Hz), 7.60 (1H, m), 7.13
(1H, d, J = 8.6 Hz), 7.06 (1H, d, J = 7.9 Hz), 6.32 (1H, s), 1.31 (9H,
s), 1.15 (9H, s). LC-MS (M + H) = 446.3.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
1
3-yl)ethyl)-4-hydroxybenzamide, 47. H NMR (400 MHz, CD3OD)
δ 8.61 (1H, s), 8.54 (1H, d, J = 5.0 Hz), 8.12 (1H, d, J = 6.4 Hz), 7.63
(1H, m), 7.19 (4H, m), 7.02 (2H, d, J = 8.2 Hz), 6.54 (2H, d, J = 8.7
Hz), 6.24 (1H, s), 1.29 (9H, s), 1.20 (9H, s). LC-MS (M + H) =
460.2.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-
3-yl)ethyl)-1-methyl-1H-imidazole-4-carboxamide, 52. 1H NMR
(400 MHz, CD3OD) δ 8.81 (1H, s), 8.46 (1H, s), 8.43 (1H, d, J =
4.76 Hz), 7.78 (1H, d, J = 8.0 Hz), 7.37 (5H, m), 6.23 (1H, s), 5.44
(1H, s), 3.63 (3H, s), 1.33 (9H, s), 1.29 (9H, s). LC-MS (M + H) =
448.2.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(thio-
phen-3-yl)ethyl)furan-2-carboxamide, 20. 1H NMR (400 MHz,
CDCl3) δ 7.37 (1H, s), 7.26 (2H, s), 7.24 (1H, s), 7.13 (1H, m), 6.99
(2H, bs), 6.89 (1H, d, J = 5.0 Hz), 6.13 (1H, m), 6.10 (1H, s), 6.06
(1H, s) 5.33 (1H, d, J = 3.6 Hz), 1.35 (9H, s), 1.29 (9H, s). 13C NMR
(100 MHz, CDCl3) δ 168.1, 159.3, 152.0, 146.4, 144.6, 137.2, 134.9,
I
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-1-(6-methylpyri-
din-3-yl)-2-oxoethyl)furan-2-carboxamide, 55. 1H NMR (400 MHz,
CD3OD) δ 8.56 (1H, s), 8.24 (1H, d, J = 8.3 Hz), 7.71 (1H, d, J = 8.3
Hz), 7.52 (1H, s), 7.41 (2H, d, J = 8.8 Hz), 7.22 (2H, m), 6.28 (1H,
dd, J = 3.6, 3.3 Hz), 6.23 (1H, s), 5.62 (1H, d, J = 3.5 Hz), 2.69 (3H,
s), 1.31 (9H, s), 1.27 (9H, s). LC-MS (M + H) = 448.3.
N-(4-(tert-Butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(1H-
1,2,3-triazol-4-yl)ethyl)furan-2-carboxamide, 60. 1H NMR (400
MHz, CD3OD) δ 7.52 (1H, d, J = 1.2 Hz), 7.44 (1H, s), 7.34 (2H,
d, J = 8.6 Hz), 7.15 (2H, bs), 6.30 (1H, s), 6.25 (1H, dd, J = 3.6, 1.6
Hz), 5.46 (1H, d, J = 3.5 Hz), 4.58 (1H, s), 1.34 (9H, s), 1.29 (9H, s).
LC-MS (M + H) = 424.2.
was incubated on ice with a final concentration of 1 mM inhibitor. A
1:1 enzyme to crystallization solution ration was used, and the
crystallization solution consisted of 14.5% PEG 20000, 50 mM MES,
pH 6.0, 50 mM potassium chloride, and 1% MPD. Crystallization trials
were set up at room temperature using the method of hanging drop
vapor diffusion. Significantly better crystal formation was observed in
the absence of sodium chloride, and crystals were sensitive to small
fluctuations in pH. Single, well-formed crystals were used for soaking
in mother-liquor supplemented with 2 mM of inhibitor at room
temperature for 3 h. MPD (15%) was used as a cryoprotectant for
freezing the crystals in liquid nitrogen where they were stored until
synchrotron time was available. Crystals were transferred from liquid
nitrogen into a stream of dry nitrogen gas at 100 K for X-ray data
collection.
X-ray data were collected on a Rayonix-300 CCD detector at the
Advanced Photon Source, Argonne National Laboratory, on beamline
21 ID-F at the Life Sciences-Collaborative Access Team (LS-CAT). X-
ray data were processed and scaled using HKL2000.52 The SARS-CoV
3CLpro−ML188 complex crystallized as a single monomer in the
asymmetric unit and in space group C2 with unit cell dimensions of a =
106.73 Å, b = 82.67 Å, c = 53.12 Å, β = 106.0°. The crystal diffracted to
a resolution 1.95 Å. The X-ray intensity data had a final Rmerge of 6.4%,
and the data were 97.8% complete overall. Additional data processing
statistics are provided in Table 4 in Supporting Information.
X-ray intensities were converted to structure-factor amplitudes by
the method of French and Wilson using the program TRUNCATE in
the CCP4 program suite.53 The initial phases for the model were
determined by the method of molecular replacement using the
program MOLREP54 in the CCP4 program suite. The search model
used for molecular replacement consisted of a monomer of SARS-CoV
3CLpro from PDB code 2ALV with all side chains intact, and all
waters and ligands removed. The final and optimal molecular
replacement solution contained a single monomer in the asymmetric
unit.
An initial round of combined positional and B-factor refinement was
performed with the program REFMAC55 in the CCP4 program suite
using a maximum-likelihood target function and no σ cutoff on
structure factor amplitudes. Initial difference Fourier maps were
calculated and visualized using the program COOT.56 The initial Fo −
Fc difference maps revealed strong (+4σ) residual electron density
peaks in the active site for the inhibitor 16-(R). A molecular model for
the inhibitor was built using the Monomer Library Sketcher program
in the CCP4 program suite, and a monomer library description was
created for refinement. Iterative rounds of refinement were performed,
and water molecules were added manually into strong (+4σ) difference
density peaks in the initial refinement stages and into peaks of (+3σ)
in the final stages of refinement. During these iterative refinements,
residual electron density consistent with two DMSO molecules from
the buffer solution were identified, and these molecules were built into
residual density and included in all subsequent refinements.
Iterative refinement using REFMAC was continued until the Rwork
and Rfree values plateaued at their lowest values, which were 21.5% and
27.1%, respectively. At this point, the coordinates for the resulting
model were submitted to the TLS (translation/libration/screw) server
to generate a multigroup TLS model.57 The resulting TLS groups were
visualized using the molecular viewer on the TLS Web site, and 20
TLS groups were chosen.58 Two rounds of TLS and restrained
refinement59 were performed in REFMAC with the weighting term set
at 0.1. The resulting and final Rwork and Rfree values were 18.7% and
23.5%, respectively, justifying the inclusion of TLS groups in the
standard refinement protocol.59 The final model coordinates have
been deposited in the PDB under accession code 3V3M.60 A summary
of the final X-ray data refinement statistics are given in Table 4 in
Supporting Information.
Expression and Purification of the SARS-CoV 3CLpro
Enzyme. An expression construct for the SARS-CoV 3CLpro enzyme
was designed to produce the exact coding region of the enzyme
released in virus-infected cells. The expression construct contained a
hexa-histidine affinity tag and a TEV protease site that is also
recognized and cleaved by SARS-CoV 3CLpro. The coding region of
SARS-CoV 3CLpro was codon-optimized and synthesized by BioBasic
(Canada) and was inserted into a pET expression vector. The enzyme
was expressed in Escherichia coli BL21(DE3) and was purified via
multistep purification protocol that employed a cobalt-charged or
nickel-charged metal-chelate HiTrap affinity column (GE Health
sciences), DEAE anion-exchange chromatography, and size-exclusion
chromatography. Purified SARS-CoV 3CLpro was then stored at −80
°C or used immediately for crystallization.
HTS Campaign Assays. 3CLpro HTS Assay Protocol. The
primary assay began with the addition of 4 μL of 3CLpro enzyme
(150 nM final concentration) in assay buffer (50 mM HEPES, 0.1 mg/
mL BSA, 0.01% Triton-X 100, 2 mM DTT) at pH 7.5 into each well of
a 1536 microtiter plate. Next, 30 nL of test compound in DMSO,
3CLpro inhibitor (300 μM final concentration) in DMSO, or DMSO
alone (0.6% final concentration) was added to the appropriate wells.
The plates were then incubated for 10 min at room temperature. After
incubation, 1 μL of 3Clpro peptide substrate (2 μM final
concentration) in 50 mM HEPES at pH 7.5 to each well. After 30
min of incubation at room temperature, 1 μL of 500 mM acetic acid
was added to each well to terminate the assay and well fluorescence
was read on a PerkinElmer Viewlux using fluorescein filters: excitation
wavelength of 480 nm (with 20 nm bandwidth) and emission
wavelength of 540 nm (with 20 nm bandwidth). All data was
normalized to that of the positive control (3CLPro inhibitor) and
wells containing DMSO only (negative control). The same protocol
was conducted for single point primary (PubChem AID 1706),
triplicate point secondary (PubChem AID 1879), and confirmatory
dose response assays (PubChem AID 1890).
PLpro Counterscreen Assay Protocol. Prior to assay, PLpro peptide
substrate and luciferase detection reagent were mixed in assay buffer
(50 mM HEPES, 0.1 mg/mL BSA, 5 mM DTT, 0.5 mM EDTA and 1
mM magnesium sulfate) at pH 7.5 and incubated for 60 min. The
assay was begun by dispensing 2.5 μL of PLpro enzyme (7.5 nM final
concentration) in assay buffer or assay buffer alone into each well of a
1536 microtiter plate. Next, 30 nL of test compound in DMSO or
DMSO alone (0.6% final concentration) was added to the appropriate
wells. The plates were then incubated for 10 min at room temperature.
Next, the enzyme reaction was initiated by dispensing 2.5 μL of the
preincubated mixture containing PLpro peptide substrate and
luciferase detection reagent (1 uM final substrate concentration).
Finally, well luminescence was read on a PerkinElmer Viewlux after 60
min of incubation at room temperature. All data was normalized to
that of the positive control (no enzyme) and wells containing DMSO
only (negative control). This protocol was used for confirmatory dose
response assays (PubChem AID 1944). Detailed assay protocols and
data generated for HTS and probe development are found at
PubChem AID 1859: pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=
1859&loc=ea.
SARS-CoV Antiviral Activity Assays. The SARS-CoV Urbani
strain was used in these experiments and was provided by the Centers
for Disease Control and Prevention. Maintenance of the Vero E6 cells
used in these studies was achieved using Dulbecco’s minimal essential
media (DMEM) (Gibco) supplemented with 100 units/mL penicillin,
100 μg/mL streptomycin (Gibco), and 10% FCS (Altanta Biologicals).
Crystallization and X-ray Structure Determination of SARS-
CoV 3CLpro in Complex with Inhibitor 16-(R). Purified SARS-
CoV 3CLpro was concentrated to 16 mg/mL in a buffer composed of
20 mM HEPES, pH 7.5, and 5 mM 2-mercaptoethanol. The enzyme
J
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
All antiviral experiments on SARS-CoV Urbani were carried out at
Purdue University using a Biosafety Level 3 suite and approved
biosafety protocols established in collaboration with the Purdue
University Institutional Biosafety Committee.
REFERENCES
■
(1) Myint, S. H. In Human Coronavirus Infections. The
Coronaviridae; Siddell, S. G., Ed.; Plenum Press: New York, 1995;
pp 389−401.
(2) McIntosh, K.; Dees, J. H.; Becker, W. B.; Kapikian, A. Z.;
Chanock, R. M. Recovery in tracheal organ cultures of novel viruses
from patients with respiratory disease. Proc. Natl. Acad. Sci. U.S.A.
1967, 57, 933−940.
(3) Ksiazek, T. G.; Erdman, D.; Goldsmith, C. S.; Zaki, S. R.; Peret,
T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J. A.; Lim, W.; Rollin, P.
E.; Dowell, S. F.; Ling, A. E.; Humphrey, C. D.; Shieh, W. J.; Guarner,
J.; Paddock, C. D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J. Y.; Cox, N.;
Hughes, J. M.; LeDuc, J. W.; Bellini, W. J.; Anderson, L. J. A novel
coronavirus associated with severe acute respiratory syndrome. N. Engl.
J. Med. 2003, 348, 1953−1966.
(4) Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H.
R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R.
A.; Berger, A.; Burguiere, A. M.; Cinatl, J.; Eickmann, M.; Escriou, N.;
Grywna, K.; Kramme, S.; Manuguerra, J. C.; Muller, S.; Rickerts, V.;
Sturmer, M.; Vieth, S.; Klenk, H. D.; Osterhaus, A. D.; Schmitz, H.;
Doerr, H. W. Identification of a novel coronavirus in patients with
severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1967−
1976.
Growth of Vero E6 cells was performed by seeding cells onto flat-
bottom, 96-well plates at a density of approximately 9 × 103 cells per
well. Vero E6 cells were either mock-infected with serum-free DMEM
or infected with 100-fold the median tissue culture infective dose of
SARS-CoV Urbani per well in 100 μL of serum-free MEM and
incubated for 1 h at 37 °C with 5% CO2. The viral inoculum was
removed after the 1 h incubation period and then 100 μL of MEM,
supplemented with 2% FCS and the 16-(R) inhibitor at concentrations
ranging from 30 to 0.1 μM, was added. Cells were then incubated for
48 h at 37 °C with 5% CO2. All controls and each inhibitor
concentration were set up in triplicate, and the antiviral assays were
performed independently on at least two separate occasions. Cell
viability was determined approximately 48 h after infection using the
CellTiter-Glo luminescent cell viability assay (Promega).
ASSOCIATED CONTENT
* Supporting Information
■
S
Additional experimental procedures, analytical data for library
compounds, in vitro assays, Lineweaver−Burk plot analysis, X-
ray crystallography statistics, and parameters. This material is
available free of charge via the Internet at http://pubs.acs.org.
(5) Ziebuhr, J. Molecular biology of severe acute respiratory
syndrome coronavirus. Curr. Opin. Microbiol. 2004, 7, 412−419.
(6) Pyrc, K.; Berkhout, B.; van der Hoek, L. The novel human
coronaviruses NL63 and HKU1. J. Virol. 2007, 81, 3051−3057.
(7) Fielding, B. C. Human coronavirus NL63: A clinically important
virus? Future Microbiol. 2011, 6, 153−159.
Accession Codes
The final model coordinates have been deposited in the PDB
under accession code 3V3M.
(8) Cui, L.-J.; Zhang, C.; Zhang, T.; Lu, R.-J.; Xie, Z.-D.; Zhang, L.-
L.; Liu, C.-Y.; Zhou, W.-M.; Ma, X.-J.; Tan, W.-J. Human
coronaviruses HCoV-NL63 and HCoV-HKU1 in hospitalized children
with acute respiratory infections in Beijing, China. Adv. Virol. 2011,
No. 129134.
(9) Zaki, A. M.; van Boheemen, S.; Bestebroer, T. M.; Osterhaus, A.
D. M. E.; Fouchier, R. A. M. Isolation of a novel coronavirus from a
man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367,
1814−1820.
(10) Yang, H.; Bartlam, M.; Rao, Z. Drug design targeting the main
protease, the Achilles’ heel of coronaviruses. Curr. Pharm. Des. 2006,
12, 4573−4590.
(11) Lai, L.; Han, X.; Chen, H.; Wei, P.; Huang, C.; Liu, S.; Fan, K.;
Zhou, L.; Liu, Z.; Pei, J.; Liu, Y. Quaternary structure, substrate
selectivity and inhibitor design for SARS 3C-like proteinase. Curr.
Pharm. Des. 2006, 12, 4555−4564.
(12) Fan, K.; Wei, P.; Feng, Q.; Chen, S.; Huang, C.; Ma, L.; Lai, B.;
Pei, J.; Liu, Y.; Chen, J.; Lai, L. Biosynthesis, purification, and substrate
specificity of severe acute respiratory syndrome coronavirus 3C-like
proteinase. J. Biol. Chem. 2004, 279, 1637−1642.
(13) Thiel, V.; Herold, J.; Schelle, B.; Siddell, S. G. Viral replicase
gene products suffice for coronavirus discontinuous transcription. J.
Virol. 2001, 75, 6676−6681.
(14) Fan, K.; Ma, L.; Han, X.; Liang, H.; Wei, P.; Liu, Y.; Lai, L. The
substrate specificity of SARS coronavirus 3C-like proteinase. Biochem.
Biophys. Res. Commun. 2005, 329, 934−940.
(15) Chuck, C. P.; Chong, L. T.; Chen, C.; Chow, H. F.; Wan, D. C.;
Wong, K. B. Profiling of substrate specificity of SARS-CoV 3CL. PLoS
One 2010, 5, No. e13197.
(16) Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld,
R. Coronavirus main proteinase (3CLpro) structure: basis for design
of anti-SARS drugs. Science 2003, 300, 1763−1767.
(17) Yang, H.; Yang, M.; Ding, Y.; Liu, Y.; Lou, Z.; Zhou, Z.; Sun, L.;
Mo, L.; Ye, S.; Pang, H.; Gao, G. F.; Anand, K.; Bartlam, M.;
Hilgenfeld, R.; Rao, Z. The crystal structures of severe acute
respiratory syndrome virus main protease and its complex with an
inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13190−13195.
(18) Bartlam, M.; Yang, H.; Rao, Z. Structural insights into SARS
coronavirus proteins. Curr. Opin. Struct. Biol. 2005, 15, 664−672.
AUTHOR INFORMATION
Corresponding Author
*Tel 616-936-8407, e-mail shaun.stauffer@vanderbilt.edu; tel
765-494-1924, e-mail amesecar@purdue.edu.
■
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
The authors thank the MLPCN (1U54 MH084659 and
MH084512) and NIH via P01 AI060915 (A.D.M.),
1R01AI085089 (A.D.M.), 2R01AI026603 (A.D.M.), and
1R03MH84162 (V.L.T.) for support, Nathan Kett and Chris
Denicola for preparative chiral SFC (VSCC), Julie Engers and
Lauren Melancon for project team management (VSCC),
Pierre Baillargeon and Lina DeLuca (Scripps) for compound
management assistance, and Katharine Emery, Jill Ferguson,
and Becky Mercer (Scripps) for administrative assistance in
reporting data and project details to the MLPCN. We gratefully
acknowledge the synchrotron beamline (LS-CAT) personnel at
the Advanced Photon Source at Argonne National Lab. Use of
the Advanced Photon Source was supported by the U.S.
Department of Energy, Office of Science, Office of Basic Energy
Sciences, under Contract No. DE-AC02-06CH11357. Use of
the LS-CAT Sector 21 was supported by the Michigan
Economic Development Corporation and the Michigan
Technology Tri-Corridor (Grant 085P1000817).
ABBREVIATIONS USED
■
SARS, severe acute respiratory syndrome; CoV, coronavirus;
3CLpro, chymotrypsin-like protease; PLpro, papain-like
protease; MCC, multicomponent condensation; 4CC, four-
component condensation reaction; BSL3, biosafety level 3
suite; MLPCN, molecular libraries probe production centers
network; SID, substance identifier; AID, assay identifier
K
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
(19) Ghosh, A. K.; Xi, D.; Johnson, M. E.; Baker, S. C.; Mesecar, A.
D. Progress in Anti-SARS coronavirus chemistry, biology and
chemotherapy. Annu. Rep. Med. Chem. 2006, 41, 183−196.
(20) Jain, R. P.; Pettersson, H. I.; Zhang, J.; Aull, K. D.; Fortin, P. D.;
Huitema, C.; Eltis, L. D.; Parrish, J. C.; James, M. N.; Wishart, D. S.;
Vederas, J. C. Synthesis and evaluation of keto-glutamine analogues as
potent inhibitors of severe acute respiratory syndrome 3CLpro. J. Med.
Chem. 2004, 47, 6113−6116.
(21) Ghosh, A. K.; Xi, K.; Ratia, K.; Santarsiero, B. D.; Fu, W.;
Harcourt, B. H.; Rota, P. A.; Baker, S. C.; Johnson, M. E.; Mesecar, A.
D. Design and synthesis of peptidomimetic severe acute respiratory
syndrome chymotrypsin-like protease inhibitors. J. Med. Chem. 2005,
48, 6767−6771.
(22) Yang, S.; Chen, S. J.; Hsu, M. F.; Wu, J. D.; Tseng, C. T.; Liu, Y.
F.; Chen, H. C.; Kuo, C. W.; Wu, C. S.; Chang, L. W.; Chen, W. C.;
Liao, S. Y.; Chang, T. Y.; Hung, H. H.; Shr, H. L.; Liu, C. Y.; Huang, Y.
A.; Chang, L. Y.; Hsu, J. C.; Peters, C. J.; Wang, A. H.; Hsu, M. C.
Synthesis, crystal structure, structure-activity relationships, and
antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
J. Med. Chem. 2006, 49, 4971−4980.
(23) Zhang, J.; Pettersson, H. I.; Huitema, C.; Niu, C.; Yin, J.; James,
M. N. G.; Eltis, L. D.; Vederas, J. C. Design, synthesis, and evaluation
of inhibitors for severe acute respiratory syndrome 3C-Like protease
based on phthalhydrazide ketones or heteroaromatic esters. J. Med.
Chem. 2007, 50, 1850−1864.
(34) Yeung, K. S.; Meanwell, N. A. Recent developments in the
virology and antiviral research of severe acute respiratory syndrome
coronavirus. Infect. Disord.: Drug Targets 2007, 7, 29−41.
(35) Regnier, T.; Sarma, D.; Hidaka, K.; Bacha, U.; Freire, E.;
Hayashi, Y.; Yoshiaki, K. New developments for the design, synthesis
and biological evaluation of potent SARS-CoV 3CLpro inhibitors.
Bioorg. Med. Chem. Lett. 2009, 19, 2722−2727.
(36) Guterman, L. Covalent drugs form long-lived ties. Chem. Eng.
News 2011, 89 (No. 36), 19−26.
(37) Turk, B. Targeting proteases: Successes, failures and future
prospects. Nat. Rev. Drug Discovery 2006, 5, 785−799.
(38) Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A
useful metric for lead selection. Drug Discovery Today 2004, 9, 430−
431.
(39) Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as
guideposts for drug discovery. Drug Discovery Today 2005, 10, 464−
469.
(40) Wu, C. Y.; Jan, J. T.; Ma, S. H.; Kuo, C. J.; Juan, H. F.; Cheng, Y.
S.; Hsu, H. H.; Huang, H. C.; Wu, D.; Brik, A.; Liang, F. S.; Liu, R. S.;
Fang, J. M.; Chen, S. T.; Liang, P. H.; Wong, C. H. Small molecules
targeting severe acute respiratory syndrome human coronavirus. Proc.
Natl. Acad. Sci. U.S.A. 2004, 101, 10012−10017.
(41) For information on the MLPCN and information on how to
request probe compounds, such ML188, see http://mli.nih.gov/mli/
mlpcn/.
(42) Chen, S.; Jonas, F.; Shen, C.; Hilgenfeld, R. Liberation of SARS-
CoV main protease from the viral polyprotein: N-terminal
autocleavage does not depend on the mature dimerization mode.
Protein Cell 2010, 1, 59−74; Erratum. Protein Cell 2010, 1, 307.
(43) Grum-Tokars, V.; Ratia, K.; Begaye, A.; Baker, S. C.; Mesecar, A.
D. Evaluating the 3C-like protease activity of SARS-coronavirus:
Recommendations for standardized assays for drug discovery. Virus
Res. 2008, 133, 63−73.
(44) Sun, H.; Luo, H.; Yu, C.; Sun, T.; Chen, J.; Peng, S.; Qin, J.;
Shen, J.; Yang, Y.; Xie, Y.; Chen, K.; Wang, Y.; Shen, X.; Jiang, H.
Molecular cloning, expression, purification, and mass spectrometric
characterization of 3C-like protease of SARS coronavirus. Protein Expr.
Purif. 2003, 32, 302−308.
(24) Xue, X.; Yu, H.; Yang, H.; Xue, F.; Wu, Z.; Shen, W.; Li, J.;
Zhou, Z.; Ding, Y.; Zhao, Q.; Zhang, X. C.; Liao, M.; Bartlam, M.; Rao,
Z. Structures of two coronavirus main proteases: Implications for
substrate binding and antiviral drug design. J. Virol. 2008, 82, 2515−
2527.
(25) Akaji, K.; Konno, H.; Mitsui, H.; Teruya, K.; Shimamoto, Y.;
Hattori, Y.; Ozaki, T.; Kusunoki, M.; Sanjoh, A. Structure-based
design, synthesis, and evaluation of peptide-mimetic SARS 3CL
protease inhibitors. J. Med. Chem. 2011, 54, 7962−7973.
(26) Chen, L.; Gui, C.; Luo, X.; Yang, Q.; Gunther, S.; Scandella, E.;
̈
Drosten, C.; Bai, D.; He, X.; Ludewig, B.; Chen, J.; Luo, H.; Yang, Y.;
Yang, Y.; Zou, J.; Thiel, V.; Chen, K.; Shen, J.; Shen., X.; Jiang, H.
Cinanserin is an inhibitor of the 3C-like proteinase of severe acute
respiratory syndrome coronavirus and strongly reduces virus
replication in vitro. J. Virol. 2005, 79, 7095−7103.
(45) McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A
common mechanism underlying promiscuous inhibitors from virtual
and high-throughput screening. J. Med. Chem. 2002, 45, 1712−1722.
(46) Barretto, N.; Jukneliene, D.; Ratia, K.; Chen, Z.; Mesecar, A. D.;
Baker, S. C. The papain-like protease of severe acute respiratory
syndrome coronavirus has deubiquitinating activity. J. Virol. 2005, 79,
15189−198.
(27) Wu, C. Y.; King, K. Y.; Kuo, C. J.; Fang, J. M.; Wu, Y. T.; Ho, M.
Y.; Liao, C. L.; Shie, J. J.; Liang, P. H.; Wong, C. H. Stable
benzotriazole esters as mechanism-based inactivators of the severe
acute respiratory syndrome 3CL protease. Chem. Biol. 2006, 13, 261−
268.
(28) Blanchard, J. E.; Elowe, N. H.; Huitema, C.; Fortin, P. D.;
Cechetto, J. D.; Eltis, L. D.; Brown, E. D. High-throughput screening
identifies inhibitors of the SARS coronavirus main proteinase. Chem.
Biol. 2004, 11, 1445−1453.
(29) Ghosh, A. K.; Gong, G.; Grum-Tokars, V.; Mulhearn, D. C.;
Baker, S. C.; Coughlin, M.; Prabhakar, B. S.; Sleeman, K.; Johnson, M.
E.; Mesecar, A. D. Design, synthesis and antiviral efficacy of a series of
potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors.
Bioorg. Med. Chem. Lett. 2008, 18, 5684−5688.
(30) Chen, L. R.; Wang, Y. C.; Lin, Y. W.; Chou, S. Y.; Chen, S. F.;
Liu, L. T.; Wu, Y. T.; Kuo, C. J.; Chen, T. S.; Juang, S. H. Synthesis
and evaluation of isatin derivatives as effective SARS coronavirus 3CL
protease inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3058−3062.
(31) Zhang, J.; Huitema, C.; Niu, C.; Yin, J.; James, M. N. G.; Eltis, L.
D.; Vederas, J. C. Aryl methylene ketones and fluorinated methylene
ketones as reversible inhibitors for severe acute respiratory syndrome
(SARS) 3C-like proteinase. Bioorg. Chem. 2008, 36, 229−240.
(32) Mukherjee, P.; Desai, P.; Ross, L.; White, E. L.; Avery, M. A.
Structure-based virtual screening against SARS-3CL(pro) to identify
novel non-peptidic hits. Bioorg. Med. Chem. 2008, 7, 4138−4149.
(33) Nguyen, T. T.; Ryu, H. J.; Lee, S. H.; Hwang, S.; Breton, V.;
Rhee, J. H.; Kim, D. Virtual screening identification of novel severe
acute respiratory syndrome 3C-like protease inhibitors and in vitro
confirmation. Bioorg. Med. Chem. 2011, 21, 3088−3091.
(47) Ratia, K.; Pegan, S.; Takayama, J.; Sleeman, K.; Coughlin, M.;
Baliji, S.; Chaudhuri, R.; Fu, W.; Prabhakar, B. S.; Johnson, M. E.;
Baker, S. C.; Ghosh, A. K.; Mesecar, A. D. A noncovalent class of
papain-like protease/deubiquitinase inhibitors blocks SARS virus
replication. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 16119−16124.
(48) Ugi, I.; Meyr, R.; Fetzer, U.; Steinbruckner, C. Versuche mit
̈
isonitrilen. Angew. Chem. 1959, 71, 386.
(49) Domling, A.; Ugi, I. I. Multicomponent reactions with
̈
isocyanides. Angew. Chem., Int. Ed. 2000, 39, 3168−3210.
(50) The protein−ligand X-ray structure of ML188-bound SARS-
3CLpro has been deposited in PDB. PDB code is 3V3M.
(51) For information on MLPCN’s probe compound ancillary
screen, see Ricerca LeadProfilingScreen: https://pharmacology.ricerca.
com.
(52) Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data
Collected in Oscillation Mode. In Macromolecular Crystallography;
Carter, C. W., Jr., Sweet, R. M., Eds.; Methods in Enzymology;
Academic Press: New York, 1997; p 307−326.
(53) CCP4. The CCP4 Suite: Programs for Protein Crystallography.
Acta Crystallogr. 1994, D50, 760−763.
(54) Vagin, A.; Teplyakov, A. MOLREP: An automated program for
molecular replacement. . J. Appl. Crystallogr. 1997, 30, 1022−1025.
L
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry
Article
(55) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of
macromolecular structures by the maximum-likelihood method. Acta
Crystallogr. 1997, D53 (Pt 3), 240−255.
(56) Emsley, P.; Cowtan, K. Coot: Model-building tools for
molecular graphics. Acta Crystallogr. 2004, D60, 2126−2132.
(57) Painter, J.; Merritt, E. A. TLSMD web server for the generation
of multi-group TLS models. J. Appl. Crystallogr. 2006, 39, 109−111.
(58) Painter, J.; Merritt, E. A. A molecular viewer for the analysis of
TLS rigid-body motion in macromolecules. Acta Crystallogr. 2005,
D61 (Pt 4), 465−471.
(59) Winn, M. D.; Isupov, M. N.; Murshudov, G. N. Acta Crystallogr.
2001, D57 (Pt 1), 122−133.
(60) Berman, H. M.; et al. The Protein Data Bank. Nucleic Acids Res.
2000, 28 (1), 235−242.
M
dx.doi.org/10.1021/jm301580n | J. Med. Chem. XXXX, XXX, XXX−XXX